{"id":"NCT03242252","sponsor":"Lexicon Pharmaceuticals","briefTitle":"Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control","officialTitle":"A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-16","primaryCompletion":"2019-03-25","completion":"2019-10-25","firstPosted":"2017-08-08","resultsPosted":"2021-06-25","lastUpdate":"2021-06-25"},"enrollment":787,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Disease Stage 3"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Sotagliflozin","otherNames":["SAR439954"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Sotagliflozin 200 mg","type":"EXPERIMENTAL"},{"label":"Sotagliflozin 400 mg","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate the superiority of Sotagliflozin 200 milligrams (mg) and Sotagliflozin 400 mg versus placebo on HbA1c reduction at 26 Weeks in participants with Type 2 diabetes who have inadequate glycemic control and moderate renal impairment.\n\nSecondary Objectives:\n\n* To assess the effects of Sotagliflozin 200 mg and 400 mg versus placebo with respect to additional measures of glycemic control, blood pressure, and body weight.\n* To evaluate the safety of Sotagliflozin 200 mg and 400 mg versus placebo.","primaryOutcome":{"measure":"Change From Baseline in HbA1c at Week 26","timeFrame":"Baseline to Week 26","effectByArm":[{"arm":"Placebo","deltaMin":-0.22,"sd":0.061},{"arm":"Sotagliflozin 200 mg","deltaMin":-0.32,"sd":0.06},{"arm":"Sotagliflozin 400 mg","deltaMin":-0.46,"sd":0.06}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2095"},{"comp":"OG000 vs OG002","p":"0.0021"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":170,"countries":["United States","Argentina","Brazil","Canada","Colombia","Germany","Hungary","Israel","Italy","Mexico","Poland","Romania","Russia","South Africa","Spain","Ukraine"]},"refs":{"pmids":["36782093"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":48,"n":260},"commonTop":["Vitamin D deficiency","Urinary tract infection","Diarrhoea","Upper respiratory tract infection","Nasopharyngitis"]}}